PLRX
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Pliant Therapeutics received FDA Fast Track designation for PLN-101095 combined with pembrolizumab to treat ICI-refractory solid tumorsAug 18, 2026
- Pliant Therapeutics dosed the first patient in the Phase 1b FORTIFY trial for solid tumorsApr 30, 2026
- Pliant Therapeutics announces interim data from PLN-101095 in immune checkpoint inhibitor-refractory advanced solid tumorsDec 4, 2025